Ginkgo Bioworks Holdings EBITDA 2020-2024 | DNA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Ginkgo Bioworks Holdings ebitda from 2020 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Ginkgo Bioworks Holdings ebitda from 2020 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$231.2B
Amgen (AMGN)	$160B
Gilead Sciences (GILD)	$137.1B
Vertex Pharmaceuticals (VRTX)	$123.3B
Bristol Myers Squibb (BMY)	$113.2B
CSL (CSLLY)	$80.1B
GSK (GSK)	$76.6B
Regeneron Pharmaceuticals (REGN)	$76.1B
Argenex SE (ARGX)	$39.3B
Alnylam Pharmaceuticals (ALNY)	$32.5B
BioNTech SE (BNTX)	$28.3B
BeiGene (ONC)	$23.9B
Biogen (BIIB)	$20.1B
Illumina (ILMN)	$15.4B
Insmed (INSM)	$15B
Genmab (GMAB)	$14.9B
Genmab (GNMSF)	$14.7B
Incyte (INCY)	$13.8B
Intra-Cellular Therapies (ITCI)	$13.7B
BioMarin Pharmaceutical (BMRN)	$13.1B
Moderna (MRNA)	$13B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
Sarepta Therapeutics (SRPT)	$10.4B
Bio-Techne Corp (TECH)	$10.4B
Vaxcyte (PCVX)	$10.3B
Exelixis (EXEL)	$9.8B
Ascendis Pharma (ASND)	$9.4B
Exact Sciences (EXAS)	$9.2B
Repligen (RGEN)	$9.1B
Bio-Rad Laboratories (BIO.B)	$8.7B